|
Volumn 162, Issue 4, 2005, Pages 817-819
|
Child psychopharmacology, effect sizes, and the big bang [14] (multiple letters)
a a a a a a a a a a a a a a a a a
a
NONE
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIDEPRESSANT AGENT;
CITALOPRAM;
PLACEBO;
SEROTONIN UPTAKE INHIBITOR;
ADOLESCENT;
CHILD;
CHILD PSYCHIATRY;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DEPRESSION;
DOUBLE BLIND PROCEDURE;
DRUG SAFETY;
HUMAN;
LETTER;
MAJOR CLINICAL STUDY;
MENTAL DISEASE;
PRIORITY JOURNAL;
PSYCHOPHARMACOLOGY;
PSYCHOPHARMACOTHERAPY;
RANDOMIZED CONTROLLED TRIAL;
SIDE EFFECT;
TREATMENT OUTCOME;
DRUG INDUSTRY;
ETHICS;
FINANCIAL MANAGEMENT;
MAJOR DEPRESSION;
METHODOLOGY;
NOTE;
PSYCHOLOGICAL ASPECT;
REPRODUCIBILITY;
STANDARD;
STATISTICS;
AGE;
ADOLESCENT;
CHILD;
CITALOPRAM;
DEPRESSIVE DISORDER, MAJOR;
DRUG INDUSTRY;
HUMANS;
PSYCHOPHARMACOLOGY;
RANDOMIZED CONTROLLED TRIALS;
REPRODUCIBILITY OF RESULTS;
RESEARCH DESIGN;
RESEARCH SUPPORT;
SEROTONIN UPTAKE INHIBITORS;
TREATMENT OUTCOME;
AGE FACTORS;
|
EID: 18344377557
PISSN: 0002953X
EISSN: None
Source Type: Journal
DOI: None Document Type: Letter |
Times cited : (4)
|
References (0)
|